Treating TRK fusion cancer: Selecting between available agents

Bookmark and Share
Published: 3 Apr 2020
Views: 1059
Prof Marc Peeters and Dr David Hong

As testing for TRK fusion cancer becomes more available across the globe, one question remains: how effective are TRK inhibitors?

Pooled data from basket trials for both larotrectinib and entrectinib have been published over the last few months, with both agents showing very promising efficacy across confirmed NTRK fusions regardless of tumour type. Join Dr David Hong and Professor Dr Marc Peeters for a comprehensive analysis of these data, and a discussion of what they mean for real-world practice.

This independent educational activity is supported by an educational grant from Bayer Pharmaceuticals. The educational content has been developed by Liberum IME and validated by an independent steering committee; Bayer Pharmaceuticals have had no influence on the content of this education.

To earn CME credits and discover further Publication to Practice sessions, please visit Oncology Knowledge into Practice.